(Solid Tumors) Do Immune Checkpoint Inhibitors Have Lower Side Effects Than Chemotherapy?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- March 30, 2020
- Reading time: 2 minutes
Updated: April 13, 2020
On January 6, 2020, D.E. Magee published a meta-analysis in Annals of Oncology: "Adverse event profiles of immune checkpoint inhibitors — including anti-PD-1/PD-L1 and anti-CTLA-4 antibodies — versus standard chemotherapy in solid tumor patients."
Analysis Design
This meta-analysis included 22 Phase 2/3 clinical trials, covering solid tumor patients in both standard chemotherapy and immune checkpoint inhibitor (ICI) therapy groups (N=12,727). Primary endpoint: Grade 3+ adverse event rate. Secondary endpoints: overall adverse event rate, treatment discontinuation rate due to adverse events, and treatment-related mortality.
Results
Primary endpoint — Grade 3+ adverse event rate:
- ICI group: 16.5%
- Standard chemotherapy group: 41.09% — ICI group had significantly lower incidence.
Secondary endpoints: The ICI group had lower overall adverse event rates, lower treatment discontinuation rates due to adverse events, and lower treatment-related mortality rates — all compared to standard chemotherapy.
Comparative Adverse Event Rates
More common in chemotherapy group:
- Fatigue: Chemotherapy 25.10% / ICI 15.83%
- Diarrhea: Chemotherapy 14.97% / ICI 11.13%
- Acute kidney injury: Chemotherapy 1.79% / ICI 1.31%
More common in ICI group:
- Colitis: ICI 1.02% / Chemotherapy 0.26%
- Pneumonitis: ICI 3.36% / Chemotherapy 0.36%
- Hypothyroidism: ICI 6.82% / Chemotherapy 0.37%
Conclusions
Based on this meta-analysis, D.E. Magee concluded: In solid tumor patients, anti-PD-1/PD-L1 and anti-CTLA-4 immune checkpoint inhibitors demonstrated significantly lower Grade 3+ adverse event rates and treatment-related mortality compared to standard chemotherapy.
Source: Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. Ann Oncol. 2020 Jan;31(1):50-60. doi: 10.1016/j.annonc.2019.10.008.
Tags: #SolidTumors #ImmuneCheckpointInhibitors
- Immunotherapy
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4